Clinical Trial Update: AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated AD-32 with or without BCG after surgery in patients with newly diagnosed or recurrent superficial bladder cancer. The study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• AD-32 (AD-32)
• BCG (Bacillus Calmette-Guérin)

Snippet

Sponsor: Anthra Pharmaceuticals | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED